Fujifilm Diosynth Biotechnologies Plans $90 Million Biomanufacturing Expansion

By Patricia Van Arnum - DCAT Editorial Director

January 11, 2019

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) of biologics and part of Fujifilm Corporation, plans to invest approximately JPY 10 billion (approximately $90 million) to expand existing production facilities at its North Carolina site. Further investments are planned at the company’s other locations with company saying details will be announced in the first quarter of 2019.

The new round of investments will include the addition of 2,000-liter single-use cell-culture manufacturing trains, cell-culture purification suites, and new microbial recovery suites to its existing facilities in North Carolina. These additions will increase cell-culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50% at its North Carolina location. The company expects that the increased production capacity will be ready for cGMP manufacture by early 2020.

Fujifilm Diosynth Biotechnologies has locations in Billingham, UK, Research Triangle Park, North Carolina and College Station, Texas.

Source: Fujifilm Diosynth Biotechnologies